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Is There a Role for
Pre-Hospital Fibrinolysis in
North America?*
Timothy D. Henry, MD†
Bernard J. Gersh, MB, CHB, DPHIL‡
inneapolis and Rochester, Minnesota
The last 25 years of reperfusion therapy for STEMI has
been a triumph. Well-designed clinical trials have provided
answers and generated new questions leading to additional
trials, and the end result is that we now have a wealth of
information. Importantly, this systematically acquired body
of knowledge has been translated into clinical practice
leading to a significant improvement in the clinical out-
comes of patients with STEMI (1).
See page 877
Although it is well accepted that primary percutaneous
coronary intervention (PCI) is the preferred reperfusion
strategy in situations when this can be achieved within 90
min of first patient contact (2,3), the key to the successful
implementation of reperfusion strategies is an awareness of
geographic diversity among countries and within countries
and an understanding that “one size does not fit all.” Key
issues, as yet unresolved, are determining what degree of
delay is acceptable in the transfer of patients from a
community hospital without PCI facilities to a hospital that
is PCI-capable and being able to determine which patients
should be pre-treated with fibrinolytic drugs and in what
setting should these be administered. One aspect of this
issue is addressed by Huynh et al. (4) in this issue of JACC:
Cardiovascular Interventions. They describe the results of a
survey of programs worldwide that have successfully used
pre-hospital fibrinolysis as a reperfusion strategy and com-
*Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the †Division of Cardiology, Minneapolis Heart Institute Foundation at
bbott Northwestern Hospital, Minneapolis, Minnesota; and the ‡Department of
ardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota.
r. Gersh reports receiving research grants from DSMBs, with Ortho-McNeil
anssen Scientific Affairs, Amorcyte, Abbott GE Healthcare, St. Jude Medical,
edispec Limited, Merck & Co., and Boston Scientific. Dr. Henry has reported that
e has no relationships relevant to the contents of this paper to disclose.ment on its underutilization in North America. What can
we learn from these results?
Randomized clinical trials provide clear evidence that
earlier treatment with pre-hospital fibrinolysis improves
survival compared with in-hospital administration and can
be safely administered in a wide variety of clinical settings
(5–7). The results of the survey reinforce this fact, but
overall use of in-hospital fibrinolysis has decreased in the
United States with the growth of regional STEMI systems
that have improved timely access to PCI. Pre-hospital
fibrinolysis may also have advantages over PCI for patients
who present early (2 h after onset of symptoms) and for
patients who are unable to receive PCI in a timely manner (2
h door-to-balloon). Despite these potential advantages, pre-
hospital fibrinolysis is seldom administered in the United
States, unlike the situation in many European countries. Is this
transatlantic divide the consequence of philosophical differ-
ences or is it a question of logistics?
The survey results do provide insights into the challenges
inherent in a pre-hospital fibrinolytic strategy. Significant
heterogeneity exists among the programs surveyed in re-
gards to program design, the ultimate reperfusion strategy,
and clinical outcomes. The design of a regional STEMI
system is critically dependent on available emergency med-
ical services (EMS) resources. For example, the majority of
programs surveyed still require the reperfusion decision to
be made by either emergency physicians or cardiologists.
Therefore, a successful pre-hospital fibrinolysis program
requires the presence of either physicians in the ambulance
or advanced care paramedics who have ready access to an
available physician. In France and Vienna, physicians are
present in nearly 100% of ambulances, which is not (and
likely never will be) the case in North America. Therefore,
fundamental to any STEMI system using pre-hospital
fibrinolysis is the availability of pre-hospital electrocardiog-
raphy and transmission (8). Pre-hospital 12-lead electrocar-
diogram availability is improving in the United States, but
still nearly one-half of STEMI systems lack this capability
(9). Reliable transmission of the results to an available
physician remains an even greater challenge in rural regions
of the United States where pre-hospital fibrinolysis might
be most needed (9).
The actual reperfusion strategy used varied significantly
in the survey. Routine angiography following lytic ranged
from 50% to 100%, and the timing of angiography varied as
well. In fact, the reperfusion strategy used by several of the
programs might be more accurately described as pharmaco-
invasive. This heterogeneity likely contributes to the vari-
ability in outcomes. Although it is nearly impossible to
compare outcomes in a survey of this type, it is interesting
to note that the mortality was highest in Sweden where use
of routine angiography was the lowest.
The survey has a number of important implications for
care of the STEMI patient in North America today. It is
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885increasingly clear that regional STEMI systems significantly
improve time to treatment, reperfusion use, and most likely
mortality (10–13). These regional STEMI systems need to
be designed with knowledge of both the availability of local
resources and local challenges. This includes location and
number of PCI centers, geography, weather, traffic, and
perhaps the most critical factor, EMS resources. Carefully
designed regional STEMI systems can meet these chal-
lenges with the use of standardized protocols and pre-
designed transfer plans. Should pre-hospital fibrinolysis be
considered as part of the reperfusion strategy?
The major challenge to successful implementation of a
pre-hospital fibrinolytic strategy is the regional variations in
EMS resources. The EMS system in the United States is
particularly fractionated with a wide range of both funding
and available services. For example, the Minneapolis Heart
Institute’s regional STEMI system, which includes 33
hospitals and 10 clinics throughout Minnesota and Wis-
consin, requires integration with nearly 50 different EMS
agencies and a wide spectrum of resource availability.
Theoretically, rural America with long distances and few
PCI centers is the ideal location for a pre-hospital fibrino-
lytic strategy, yet paradoxically presents the greatest chal-
lenges due to scarce EMS resources. Many ambulances in
rural America are staffed by volunteers with only basic life
support training and pre-hospital electrocardiography capa-
bility is much less common than for urban EMS systems.
Funding for both training and equipment is frequently the
greatest challenge.
Perhaps the most important insight from the survey is
that fibrinolytic and PCI reperfusion strategies should no
longer be considered mutually exclusive. Many of the
programs surveyed use a pharmacoinvasive approach with
pre-hospital fibrinolysis followed by immediate transfer to a
PCI center for early angiography and revascularization. The
popularity of the pharmacoinvasive approach has been
driven by the results of recent randomized clinical trials that
have demonstrated superiority of this approach over fibri-
nolysis followed by standard care (revascularization only for
failed reperfusion or recurrent ischemia) (14–16). A recent
meta-analysis of 7 trials enrolling nearly 3,000 patients
confirmed the benefits of the pharmacoinvasive strategy
with a significant reduction in the combined endpoint of
death/reinfarction at 30 days, without an increase in major
bleeding or stroke (17). Current European Society of
Cardiology guidelines now recommend routine transfer to a
PCI center with early angiography and revascularization
within 3 to 24 h (3). As illustrated by the survey, the specific
pharmacologic regimen and the timing of early angiography
remain unclear. Large regional STEMI systems in the
United States frequently employ a combination of reperfu-
sion strategies (10,11,13). The Minneapolis Heart Insti-
tute’s Level 1 MI program uses a pharmacoinvasive strategy
for patients with an expected total door-to-balloon time120 min (hospitals 60 to 120 miles from the PCI center
[10]), whereas the Mayo Clinic STEMI system uses fibri-
nolysis for early presenters followed by transfer and early
angiography (11). Results from 5 high-volume PCI centers
indicate a reduced-dose fibrinolytic strategy with early PCI
may have advantages over PCI alone (18).
The majority of patients with STEMI who present to
PCI centers in the United States are currently being treated
with door-to-balloon times 90 min. Therefore, remaining
advances in the management of STEMI will likely come
from non-PCI hospitals where total door-to-balloon times
for patients transferred from non-PCI hospitals remain
suboptimal. Well-designed regional STEMI systems re-
quire careful consideration of the optimal reperfusion strat-
egy taking into account local resources and challenges.
Whether pre-hospital fibrinolysis will become more com-
mon in North America is uncertain, but the lessons learned
from this survey from successful programs around the world
provide important insights for the development of regional
STEMI systems. In the current era, it is not just the
nature of the reperfusion therapy that is important but
the speed and efficacy of delivery to all eligible patients,
which will continue to improve the outcome of STEMI
patients worldwide.
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